Can avatrombopag (Sucoxin) be taken during pregnancy and its risk warnings

Avatrombopag (Avatrombopag) is an oral thrombopoietic drug, mainly used in patients with chronic liver disease-related thrombocytopenia and immune thrombocytopenia (ITP). However, clinical evidence for its use during pregnancy is still limited, so it is not recommended as a routine pregnancy treatment option. Existing data suggest that the drug may affect the platelet production pathway and may cross the placenta, theoretically having the potential to cause adverse effects on fetal development. Therefore, if pregnant women experience thrombocytopenia, they should choose safer and evidence-based treatment options under the guidance of professional doctors and avoid taking avatrombopag on their own.

Women who are pregnant or planning to become pregnant and are taking avatrombopag should consult their doctor before becoming pregnant to assess the risks and discuss a plan to discontinue the drug. Since there have been no large-scale clinical studies of this drug during pregnancy and the safety level is not clear, the potential risk is theoretically higher in early pregnancy, especially during the critical stage of embryonic organ development (first trimester). Some patients may only discover they have taken the drug after becoming pregnant, in which case they need to contact their doctor as soon as possible for a risk assessment, such as monitoring fetal development, assessing maternal platelet levels, and whether alternative treatments are needed.

Management of thrombocytopenia during pregnancy is usually different than during non-pregnancy because many medications are not safe during pregnancy. Lower-risk regimens such as monitoring and observation, short-course hormone therapy, and intravenous immune globulin (IVIG) are more commonly used clinically. However, avatrombopag is usually not the first choice due to the lack of sufficient evidence to support its safety. If the platelet count is too low during pregnancy and reaches a level that requires treatment, doctors will develop an individualized plan based on gestational age, maternal condition, and bleeding risk, and fully avoid uncertain risks; if necessary, alternative drugs will be used under strict supervision after assessing the safety of the mother and baby.

In conclusion, avatrombopag is not recommended for use during pregnancy, especially in the absence of sufficient evidence of safety. If women who are preparing to become pregnant, are pregnant, or breastfeeding need treatment for thrombocytopenia, they should communicate with the hematology department and obstetrician in a timely manner instead of adjusting their medication on their own. At the same time, patients should avoid all unnecessary drugs as much as possible during pregnancy, and have regular follow-up visits to monitor platelet levels and fetal development. If there are questions about the use of avatrombopag, it is best for a professional physician to make the final decision based on clinical data and maternal and fetal risk assessment to ensure the effectiveness and safety of the treatment.

Reference materials:https://www.drugs.com/